Antibiotic shield tested for blood cancer patients on azacitidine
NCT ID NCT03594149
First seen Jan 04, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study looked at whether giving the antibiotic levofloxacin can prevent serious infections in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who are being treated with azacitidine. Infections are a major risk for these patients. The study enrolled 60 adults and compared those who received levofloxacin to those who did not, tracking fevers and infections during the first three treatment cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU Lille
Lille, 59037, France
-
CHU Amiens
Amiens, 80000, France
-
CHU Caen
Caen, 14033, France
-
Centre Henri Becquerel
Rouen, 76000, France
Conditions
Explore the condition pages connected to this study.